News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
BioNxt announces progress in cladribine oral thin film development, with focus on bioavailability improvement and human clinical study for Multiple Sclerosis. Expansion into Myasthenia Gravis also planned -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
BioNxt reports successful preclinical study results for sublingual oral dissolvable film (ODF) cladribine formulation in treating Multiple Sclerosis (MS), achieving higher systemic drug delivery than oral tablets -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
BioNxt Solutions reports successful comparative pharmacokinetics study in pigs for sublingual cladribine ODF formulation, showing superior bioavailability and potential benefits for Multiple Sclerosis therapy. Internal analysis ongoing -
